Is SVR12 As Good As SVR24?

In patients with chronic Hepatitis C virus (HCV) infection, a sustained viral response to treatment regimens 12 weeks after therapy (SVR12) is a good indicator that the response will be maintained until week 24 (SVR 24), based on an analysis of pooled clinical trial data published in the June issue of

Read more

New Ways to Study HCV, Genotypes 3 and 4

Researchers can now study replication of Hepatitis C virus genotypes 3 and 4 in cultured cells, described in 2 articles in the January issue of Gastroenterology. These new tools will improve our understanding of how they cause liver disease, and could lead to new treatments. HCV leads to chronic infection

Read more

It’s Not Easy to Diagnose Intermediate-Stage Liver Fibrosis

Biopsy has a low level of diagnostic performance for liver fibrosis stages F2 and F1. The recommendation for biopsy analysis, instead of non-invasive tests, for diagnosis of intermediate stages of fibrosis is therefore misleading, according to the June issue of Clinical Gastroenterology and Hepatology. Noninvasive tests such as FibroTest are

Read more

A Special Issue on Viral Hepatitis

The May issue of Gastroenterology features a very special supplement—“Viral Hepatitis: A Changing Field”—comprising 17 review and commentary articles from international leaders in hepatitis treatment and research. The issue provides insight into the rapid progress made in the treatment and management of patients with viral hepatitis, as well as our

Read more

Can We Treat Chronic HCV Infection Without Interferon?

A potent combination of 2 drugs that directly target the hepatitis C virus (HCV) is effective in patients with chronic infection, and doesn’t require interferon therapy, according to an article in the December issue of Gastroenterology. Patients infected with HCV genotype-1 are usually treated with peginterferon and ribavirin, but approximately

Read more

How Does Deferasirox Reduce Liver Fibrosis?

Liver fibrosis is reduced in patients with iron overload β-thalassemia and hepatitis C given the iron chelator deferasirox, according to Yves Deugnier et al. in the October issue of Gastroenterology. The liver is the main site of iron accumulation in patients with iron-overload disorders. Storage of excess iron in the

Read more